ClinicalTrials.gg

Program

seralutinib

Also written as “Seralutinib”, “GB002 (seralutinib)” and “GB002”.

Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary, led by 4 companies.

Furthest: phase 3, since Jun 30, 20208 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GB002, Inc., a wholly owned subsidiary of Gossamer Bio30 open or runningphase 2since Jun 30, 2020Mar 8, 2018none ahead
GB00220 open or runningphase 3since Jun 28, 2023Jun 28, 2023none ahead
Gossamer Bio USA21 open or runningphase 3since Jan 19, 2024Mar 23, 2021Dec 2026phase 3 · NCT06274801
Zhejiang Echon Biopharm11 open or runningphase 1since Apr 30, 2024Apr 30, 2024none ahead

Also a collaborator on its studies: Chiesi Farmaceutici and Pulmokine.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2018First study: phase 1 study in Safety IssuesNew to GB002, Inc., a wholly owned subsidiary of Gossamer BioGB002, Inc., a wholly owned subsidiary of Gossamer Bio · NCT03473236 · 66 enrolled · United States
  2. Apr 22, 2019Phase 1 study in Pulmonary Arterial HypertensionGB002, Inc., a wholly owned subsidiary of Gossamer Bio · NCT03926793 · 8 enrolled · United States, United Kingdom
  3. Jun 30, 2020Phase 2 study in Familial Primary Pulmonary HypertensionGB002, Inc., a wholly owned subsidiary of Gossamer Bio · NCT04456998 · 86 enrolled · United States, Australia, Austria and more
  4. Mar 23, 2021Gossamer Bio USA’s first study: phase 2 study in Pulmonary Arterial HypertensionNew to Gossamer Bio USAGossamer Bio USA · NCT04816604 · 74 enrolled · United States, Australia, Czechia and more
  5. Jun 28, 2023GB002’s first study: phase 3 study in Pulmonary Arterial HypertensionNew to GB002GB002 · NCT05934526 · 390 enrolled · United States, Argentina, Australia and more
  6. Jan 19, 2024Phase 3 study in Pulmonary Arterial HypertensionGossamer Bio USA · NCT06274801 · 330 planned · United States, Argentina, Australia and more
  7. Apr 30, 2024Zhejiang Echon Biopharm’s first study: phase 1 study in HealthyNew to Zhejiang Echon BiopharmZhejiang Echon Biopharm · NCT06423261 · 100 enrolled · China
  8. Sep 12, 2025Phase 3 study in Hypertension, PulmonaryGB002 · NCT07181382 · 480 enrolled · United States, Israel

Ahead

  1. Dec 2026Primary completion: phase 3 study in Pulmonary Arterial HypertensionGossamer Bio USA · NCT06274801

TargetBeta

“Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
quizartinibruleDaiichi Sankyophase 322

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07181382Hypertension, Pulmonary · United States, Israel3SuspendedGB002Dec 2028480
NCT06423261Healthy · China1Active, not recruitingZhejiang Echon BiopharmDec 30, 2025100
NCT06274801Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3RecruitingGossamer Bio USADec 2026330
NCT05934526Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedGB002Nov 27, 2025390
NCT04816604Pulmonary Arterial Hypertension · United States, Australia, Czechia and more2TerminatedGossamer Bio USASep 9, 202674
NCT04456998Familial Primary Pulmonary Hypertension · United States, Australia, Austria and more2CompletedGB002, Inc., a wholly owned subsidiary of Gossamer BioOct 17, 202286
NCT03926793Pulmonary Arterial Hypertension · United States, United Kingdom1CompletedGB002, Inc., a wholly owned subsidiary of Gossamer BioMay 5, 20218
NCT03473236Safety Issues · United States1CompletedGB002, Inc., a wholly owned subsidiary of Gossamer BioDec 3, 201866

How it is read

Names in the registry

  • “Seralutinib”, 3 entries
  • “GB002 (seralutinib)”, 2 entries
  • “GB002”, 2 entries
  • “GB002 Recombinant Peptide Inhalation Solution”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.